Main plenary
Tuesday, 27 April l UBS
Live
| Singapore Standard Time (SST) / Hong Kong Time (HKT)
10:00 – 10:10
Opening address
Edmund Koh, Member of the UBS Group Executive Board President UBS Asia Pacific of UBS Group AG and UBS AG
10:10 - 10:30
Keynote address
Ageing is a disease, and that disease is treatable. In extraordinary times like this, a health crisis that puts almost everything in jeopardy has also renewed our perspective on the true meaning of longevity. With COVID-19 vaccines being developed at breakneck speeds, we remain cautiously optimistic about the future of healthcare. How has advancements in preventive health, target treatment and healthtech paved the way for the next decade and beyond? While we are already living longer, can we also live better?
David A. Sinclair, Ph.D., A.O. Professor, Department of Genetics, Harvard Medical School
10:30 - 11:00
Future of preventive care
It has been more than a year since the COVID-19 pandemic brought the world to a grinding halt. Vaccines are developed and inoculated at breakneck speeds. What protection does the vaccine have against variants of the virus? Why are Asian countries lagging in vaccine rollouts and what is the lasting impact of the pandemic?
Healthcare Summit 2021
Stéphane Bancel CEO, Moderna
Moderator:
Eric Potoker
Executive Director, UBS AG
11:00 – 11:30
Future of personalised medicine
Is personalised treatment & healthcare the way forward? How far have we come in treatment that uses therapy that targets specific genes and proteins for cancer patients? What are the tools that are making drug discovery and development more efficient and predictable? How would precision medicine shape the future in oncology therapeutics?
William G. Kaelin, Jr., M.D. 2019 Nobel Laureate
Professor, Medicine, Harvard Medical School
Moderator:
Nicole Goh
Executive Director, UBS AG
11:30 – 12:00
Future of healthtech
What new care models are emerging to push telemedicine beyond mere virtualisation?
What models have successfully crossed borders and have become scalable in multiple geographies?
Lily Xu CFO, ClouDr
Matteo Berlucchi
CEO and Co-Founder, Healthily
Moderator:
14:00 - 14:30
AUM Biosciences
AUM Biosciences is at the forefront of disrupting R&D in oncology, rapidly delivering innovative medicines and technologies to patients. Founder and CEO Vishal Doshi will discuss how it is employing a portfolio model of developing next generation targeted oncology and immuno-oncology therapies, particularly for cancers with a clear genetic markers and undruggable targets and what’s over the horizon.
Vishal Doshi
Founder and CEO of AUM Biosciences
Moderator:
Alfred Li
Executive Director, UBS AG Investment Bank
15:30 – 16:00
MiRXES
MiRXES is a Singapore-headquartered biotechnology company that translates research discoveries to deliver world-leading multi-cancer early detection. CEO and Co-Founder Dr Zhou Lihan will share the story of MiRXES’ start, and history producing the world’s first molecular blood test for early detection of gastric cancer, microRNA and diagnostics in Singapore, and his company’s 5-year pipeline.
Dr. Zhou Lihan
Co-founder & CEO of MiRXES
Moderator:
Alfred Li
Executive Director, UBS AG Investment Bank Gmax Bio International
Gmax is a clinical stage company established in 2010 and headquartered in Hangzhou, China. It’s a global company focusing on R&D, production and commercialisation of antibody drugs targeting GPCRs. Gmax mainly works in cardiovascular, metabolic and cancer areas, with drug development programs in different stages of clinical trials. Dr. Shuqian Jing
Founder, Chairman and CEO of Gmax Bio International
Moderator:
Alfred Li
Executive Director, UBS AG Investment Bank 14:30 – 15:00
15:00 - 15:30
InferVision
InferVision’s CEO Kuan Chen will talk about InferVision’s vision and core services, the InferRead Solutions for high-speed, high-accuracy diagnostics, and InferScholar Center, the AI-research integrated research and data platform, as well as clinical partnerships throughout the world.
Kuan Chen
Founder and CEO of InferVision
Moderator:
Alfred Li
Executive Director, UBS AG Investment Bank
Private company showcase
Breakout sessions -
14:00 onwardsYou may view these sessions at your own leisure.
The real cost of healthcare
Sharing of the ASEAN landscape and implications for investors
Providing financing for healthcare system amid a global pandemic is a challenge for governments. What are the tangible and intangible costs of the COVID-19 pandemic? How can public and private sectors work together to cushion cost impact on the coronavirus?
Healthspan vs. lifespan: How to live longer and better
What is the root cause of chronic diseases like cancer, Alzheimer’s and cardiovascular diseases? The answer is simpler than what we think: it’s ageing. With a larger population growing older in developed nations like Japan and Singapore, it is projected by the World Health Organization that there will be 2 billion people over 60, up from 900 million in 2015. And while people are living longer, have we overlooked the significance of living better? Join Professor Brian Kennedy, Director of the Centre of Healthy Longevity at the National University Health System (NUHS) for a breakout session on his insights on ageing and how to overcome its effects.
Sustainable development goals on healthcare
We will explore emerging solutions in Asia, and how investors can mobilise the healthcare sector to make it work better for all.
Moderator: Patricia Quek Managing Director, UBS AG Moderator: Stephanie Choi Director, UBS AG Dr. Phua Kai Hong
Adjunct Senior Research Fellow at the Institute of Policy Studies
Moderator:
Debra Tay Executive Director, UBS AG
Professor Brian Kennedy Director,
Yong Loo Lin School of Medicine National University of Singapore
Farouk Meralli
10:00 – 10:10
Opening address
Edmund Koh
Member of the UBS Group Executive Board
President UBS Asia Pacific of UBS Group AG and UBS AG
Edmund Koh became a member of the GEB and was appointed President UBS Asia Pacific of UBS Group AG and UBS AG in January 2019. He is also Head Wealth Management Asia Pacific since 2016 as well as Country Head Singapore since 2012.
He joined UBS in February 2012 as Group Managing Director, heading the UBS Wealth Management South East Asia and Asia Pacific Hub. Edmund, a Singaporean, is also a member of the UBS Global Wealth Management Executive Committee and Global Head of Affluent.
Mr. Koh has more than 30 years' experience in senior roles in financial services. Prior to UBS, he was at Taiwan-based Ta Chong Bank where he served as President and Director from 2008 to 2011. From 2001 to 2008, Mr. Koh was Managing Director and Regional Head, Consumer Banking of DBS Bank in Singapore. In 2001, he became CEO of Alverdine Bank; two years earlier he held the same position for Prudential Assurance, both companies based in Singapore.
Edmund holds a Bachelor of Science in Psychology from the University of Toronto, Canada.
10:10 - 10:30
Keynote address
David A. Sinclair, Ph.D., A.O.
Professor, Department of Genetics, Harvard Medical School
David A. Sinclair, Ph.D., A.O. is a Professor in the Department of Genetics, Blavatnik Insitute, and co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. He is best known for his work on
understanding why we age and how to slow its effects. He obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney, in 1995 and did his postdoctoral research at M.I.T. with Dr. Leonard Guarente where he co discovered a cause of aging for yeast as well as the role of Sir2 in epigenetic changes driven by genome instability and aging.
In 1999 he moved to Harvard Medical School and has primarily focused on understanding why we age and the role of protective enzymes called the sirtuins, which respond to changing NAD+ levels, exercise, and caloric restriction (CR). The Sinclair lab was the first to identify a role for NAD biosynthesis in the regulation of lifespan and first showed that sirtuins are involved in CR’s benefits in mammals and identified the first small molecules that activate SIRT1 (STACs). His lab is alos working on epigenetic changes as a driver of aging and the use of reprogramming factors to reset the age of cells and tissues. He is the New York Times bestselling author of Lifespan (2019), has published over 200 scientific papers, is a co-inventor on over 50 patents, and has co-founded biotechnology companies in the areas of aging, vaccines, diabetes, infectious diseases, immunity and cancer.
10:30 - 11:00
Future of preventive care
Stéphane Bancel
CEO, Moderna
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Qiagen N.V. and Indigo. He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
10:30 - 11:00
Future of preventive care
Eric Potoker
Executive Director, UBS AG
Eric has covered health care as an analyst and portfolio manager since 2002. He previously worked at multi-billion-dollar long/short funds JL Advisors and Karsch Capital Management as the health care sector head,
and at the family office 40 North as a portfolio manager and sector head.
Eric has covered the health care sector broadly, including pharmaceutical and biotech companies, as well as health care services and medical device companies. He uses a deep fundamental research approach to stock picking, in an effort to identify attractive growth and value opportunities.
11:00 – 11:30
Future of personalised medicine
William G. Kaelin, Jr., M.D.
2019 Nobel Laureate
Professor, Medicine, Harvard Medical School
William Kaelin obtained undergraduate and M.D. degrees from Duke University and completed his internal medicine training at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in medical oncology at the Dana-Farber Cancer Institute and a postdoctoral fellow in the laboratory of David Livingston, during which time he was a McDonnell Scholar. He is currently the Sidney Farber Professor of Medicine, in the Department of Medicine at the Dana-Farber Cancer Institute and the Brigham and Women's Hospital, Harvard Medical School. A Nobel laureate, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. He is a member of the American Society of Clinical Investigation, the American College of Physicians, the National Academy of Sciences, the American Academy of Arts & Sciences and the National Academy of Medicine. He recently served on the NCI Board of Scientific Advisors, the AACR Board of Trustees, and the IOM National Cancer Policy Board. He has received numerous awards including the MSKCC Paul Marks Prize, the AACR Richard and Hinda Rosenthal Prize, a Doris Duke Distinguished Clinical Scientist Award, the Canada International Gairdner International Award, the ASCI Stanley J. Korsmeyer Award, the Scientific Grand Prix of the Foundation Lefoulon-Delalande and the Institute of France, the Albert Lasker Prize, the Helis Award, and the Massry Prize.
William G. Kaelin, Jr., a 2019 Nobel laureate, is the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School and a Howard Hughes Medical Institute Investigator.
11:00 – 11:30
Future of personalised medicine
Nicole Goh
Executive Director, UBS AG
Nicole Goh is Executive Director and Head of Equity Research in Malaysia. In her current capacity she covers ASEAN Healthcare as well as Malaysia Strategy, Consumer and Gaming, which her teams have been top ranked (#2 for Healthcare and #3 for Malaysia) in the Institutional Investor survey 2020.
11:30 – 12:00
Future of healthtech
Lily Xu
CFO, ClouDr
Ms. Xu Lili, aged 39, has more than 16 years experience in financial management. She is now the Chief Financial Officer of ClouDr (China’s Largest SaaS-based Digital Chronic Condition Management Platform). From March 2014 to September 2020, she was appointed as the Chief Financial Officer and Executive Director for Tongdao Liepin Group (HKEx.6100). She was primarily responsible for overseeing the corporate finance, handling investor relationships, and overseeing all the investments and acquisitions of the group. Prior to that, Ms. Xu held various positions at General Electric Company (NYSE: GE), including as the Chief Financial Officer of GE Power Generation Services China, from January 2005 to March 2014. Ms. Xu received a bachelor’s degree in International Business from Nanjing University in June 2003 and a Master of Science degree in Local Economic Development from the London School of Economics and Political Science in November 2004. Ms. Xu is a public accountant certified by the Board of Accountancy of Washington State of the United States.
Ms. Xu also serves as the Director for MINISO Group (NYSE: MNSO) and Yalla Group (NYSE: YALA).
11:30 – 12:00
Future of healthtech
Matteo Berlucchi
CEO and Co-Founder, Healthily
Matteo Berlucchi is a serial digital entrepreneur with 25 years' experience launching and scaling online businesses.
Passionate about helping people find what they're looking for, Matteo launched the first internet property search website in Europe in 1995. By 2006, he had created the first live news aggregator, followed by the first social discovery platform for books in 2010 and Your.MD, now Healthily (www.livehealthily.com), in 2015.
Matteo is a UBS Global Visionary, Entrepreneur in Residence at ETH Zurich and a regular speaker at international conferences. He has a doctoral degree in theoretical physics and has carried out post-graduate research in virtual reality at Imperial College London. He's a father of three, expert in Italian wines and a self-confessed hypochondriac.
11:30 – 12:00
Future of healthtech
Sundeep Gantori
Executive Director, UBS AG
Sundeep Gantori is the equity analyst responsible for the global technology sector, Asia ex Japan Focus 20 list and Taiwan equity market.
Sundeep joined UBS Global Wealth Management as an equity analyst in February 2007 and his coverage mainly focuses on both global and Asian technology sectors including semico nductors, hardware, internet and software & services. Additionally, Sundeep is also responsible for Asia ex Japan Focus 20, CIO's highest convictions stock ideas in the region and Taiwan equities.
Before joining UBS, Sundeep worked as an equity analyst in PCS Securities, an Indian brokerage firm where he was covering the Indian IT & Telecom sectors.
Dr. Phua Kai Hong
Adjunct Senior Research Fellow at the Institute of Policy Studies
Dr Kai Hong PHUA is a health policy expert at the Institute of Policy Studies, Singapore and currently Visiting Professor to Nazarbayev University, Kazakhstan. He was previously tenured at the Lee Kuan Yew School of Public Policy, National University of Singapore and Associate Professor & Head, Health Services Research at the Department of Community, Occupational & Family Medicine in the Faculty of Medicine. He graduated with honours cum laude from Harvard University and received graduate degrees from the Harvard School of Public Health and the London School of Economics & Political Science (specializing in Health Economics).
He recently lectured to the ASEAN Secretariat and conducted executive programs to leading European universities. He was the co-lead and corresponding author of the overview article in the Lancet Series on Health in Southeast Asia (2011), lead Guest Editor of Social Science & Medicine special issue on Health Systems in Asia (2016) and a co-author of Ageing in Asia: Contemporary Trends and Policy Issues (2018).
He delivered the ST Lee Lecture 2012 at the Menzies Centre for Health Policy, University of Sydney and the Australian National University. He was a former Chair, Technical Advisory Group for Health Sector Development, WHO Western Pacific Regional Office, and a member of the WHO Expert Committee on Economics of Healthy Ageing. He has served on the councils of social service organizations in Singapore and last served on the Fees Benchmark Advisory Committee, Ministry of Health.
14:00 onwards
The real cost of healthcare
Sharing of the ASEAN landscape and implications for investors
14:00 onwards
The real cost of healthcare
Sharing of the ASEAN landscape and implications for investors
Patricia Quek
Managing Director, UBS AG
Patricia Quek currently leads the Singapore, Malaysia & GFIM (SG) teams. Prior to this, she led the Ultra High Net Worth (UHNW) Indonesia team & incepted the Global Family Office (GFO) team for SEA. She has been the WM Healthcare sector lead since 2010 and the WM SEA Sustainable Finance lead since 2020.
Patricia joined UBS in 1996 and has more than 25 years' experience delivering integrated solutions across wealth management, investment bank and asset management to Billionaires, UHNW clients, global family offices, private and public listed companies. She brings with her extensive knowledge of global financial markets, investments, corporate advisory services, family advisory services and knowledge of regulations in key operating markets. She sits on the WM management committee responsible for location decisions.
• Leads and manages a team of client advisors focused on serving Ultra High Net Worth (UHNW) entrepreneurs and families from Singapore, Malaysia, Indonesia and China
• Extensive knowledge of the Asia Pacific markets and business practices
• Solid understanding of capital markets and businesses due to global markets and corporate banking background
• More than 20 years of experience in the finance industry
• Joined UBS in 2017
• Fluent in English and Mandarin and conversant in Bahasa, Cantonese, Teochew and Russian
Summary of experience
Education and professional qualifications
• Master of Advance Studies in Finance from University of Bern
• Master of Science in Wealth Management from University of Rochester, Simon Business School
• Master of Applied Finance from Kaplan Professional
• Bachelor of Commerce from University of Melbourne
• Advanced Diploma in Wealth Management from Kaplan Professional
• Chartered Financial Analyst (CFA)
• Attended the Leading Global Businesses program at Harvard Business School
Activities and interests
• Enjoys keeping fit through sports such as scuba diving and golf
• Likes traveling and reading 14:00 onwards
Healthspan vs. lifespan: How to live longer and better
Debra Tay
Executive Director, UBS AG
14:00 onwards
Healthspan vs. lifespan: How to live longer and better
Professor Brian Kennedy
Director, Yong Loo Lin School of Medicine
National University of Singapore
Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of delaying, detecting, and preventing human aging and associated diseases. He is a Professor in the Departments of Biochemistry and Physiology at National University Singapore and Director of the Centre for Healthy Longevity in the National University Health System. From 2010 to 2016 he was the President and CEO of the Buck Institute for Research on Aging.
14:00 onwards
Sustainable development goals on healthcare
Farouk Meralli
Founder and CEO, mClinica
Farouk Meralli is the Founder of mClinica Pharmacy Solutions, a healthcare startup connecting pharmacies in emerging markets through a common mobile technology platform. mClinica operates across southeast Asia connecting over 45,000 pharmacies and 190,000 pharmacy professionals which reach over 150 million patients. Previously, Farouk held senior roles in strategy and product development at global pharmaceutical companies Pfizer, Sanofi, and Roche.
He is the recipient of the Harvard Alumni Public Health Innovator Award, an Endeavor Entrepreneur, a Board Advisor at PATH, and the Chair and Founder of non profit organization, Borderless World Volunteers. He holds a Bachelors in Biomedical Sciences and International Development Studies from McGill University and a Masters in Health Policy and Management from the Harvard University.
14:00 onwards
Sustainable development goals on healthcare
Stephanie Choi
Director, UBS AG
Stephanie Choi is a Sustainable Investing (SI) Strategist in the Chief Investment Office, Global Wealth Management. Stephanie was most recently Partner at Sustainable Finance initiative, an investment community that is both a
consultancy for regional family offices in impact strategy development and implementation, and an advocacy for broader SI development in Asia. Prior to her specializing in sustainable and impact investing, Stephanie began her career at Citigroup Global Markets, where she gained 11 years’ experience in institutional advisory with a focus on Asian equities & equity-linked products.
14:00 – 14:30
AUM Biosciences
Vishal Doshi
Founder and CEO AUM Biosciences
Mr. Vishal Doshi is the Founder and CEO of an award winning oncology focused biotech company AUM Biosciences.
AUM is challenging status quo, and is ready to enable significant disruptions within the existing pharma and biotech landscape. AUM’s immediate focus is on development of novel targeted oncology therapies, particularly for cancers with a “clear genetic marker” and “drugging the undruggable”. He also serves as the Chairman of AUM’s board of directors. Under his leadership, AUM has become a clinical stage company, and developed a portfolio of transformative cancer medicines in a very short time. Additionally, to drive the vision, he has been able to secure a multi-year AI partnership to drive drug discovery, as well as a 135M+ partnership to drive AUM’s business expansion in China. Within the first year of
operations, AUM was awarded 2019 Asia-Pacific Biotech Entrepreneurial Company of The Year by Frost and Sullivan. A registered pharmacist by training, Mr. Doshi is an experienced senior management with extensive experience in commercial deal structuring over a 4Billion USD including JV, Licensing, M&A and Long term strategic partnerships.
He is a nominated Young Global Leader by the World Economic Forum. He is also a Key Opinion Leader with the Korean Ministry of Health initiative called KHIDI. He has graduated as a pharmacist from University of Mumbai and is a trained medicinal chemist with a Masters degree from Kingston University for his research in aromatase inhibitors for treatment of breast cancer.
14:30 – 15:00
Gmax Bio International
Dr. Shuqian Jing
Founder, Chairman and CEO, Gmax Bio International
Dr Jing holds a Ph.D. of University of California and was awarded “China Outstanding Youth Funding”.
He is also a Professor Level Senior Engineer; Professor at Academy of Military Medical Sciences and Professor at Beijing Normal University.
Dr. Jing has 30+ years of biopharmaceutical industry experiences at Salk Institute, Bristol-Myers Squibb,
15:30 – 16:00
MiRXES
Dr. Zhou Lihan
Co-founder & CEO of MiRXES
Lihan co-founded and serves as CEO of MiRXES, a Singapore headquartered biotechnology company with the mission to develop accurate, affordable and actionable early cancer detection solutions. He oversees MiRXES’ operations and manages joint ventures with leading clinical consortia and pharmaceutical companies in developing novel RNA diagnostic and companion diagnostic tests. In a short six-year period, MiRXES has grown from a 3-man team operating out of a shared laboratory in A*STAR to a global operation with more than 100 employees across 5 R&D labs, 2 manufacturing facilities, 1 clinical diagnostic lab and 4 country offices in Singapore, US, Japan and China. MiRXES has successfully raised USD $43 million venture funding since 2016, which is among the highest raised by an Asia based diagnostic start-up.
In Feb 2020, MiRXES was engaged by the Singapore government agencies to manufacture and supply COVID-19 test kits in response to the escalating global pandemic. The FortitudeTM COVID-19 RT-PCR Test, developed by A*STAR, TTSH and manufactured by MIRXES, has become one of the most widely used tests globally, with deployment in more than 45 countries to date.
Prior to founding MiRXES, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel microRNA qPCR assay platform and an integrated workflow for microRNA biomarker and therapeutic target discovery.
Lihan has a PhD in Biochemistry from the National University of Singapore. He was trained as a molecular neurobiologist with a broad mastery in other domains including qPCR technology, gene delivery, tumor targeting nanoparticles and nanostructure enhanced clinical analyte detection. Lihan has authored and co-authored more than 20 peer-reviewed publications and several patent applications.
In 2015, Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35. MIRXES has been recognized by a number of Singapore and overseas awards including Singapore’s Most Promising Start-up in 2016 and Singapore’s Fastest Growing Companies in 2020.
15:00 – 15:30
InferVision
Kuan Chen
Founder and CEO, InferVision
CHEN Kuan is Founder and Chairman of Infervision Medical Technology. He is also Vice Chairman of the Healthcare AI Committee of the China Association of Medical Devices Industry, as well as Vice Chairman of China Medical Imaging AI’s Industry-University-Research Application Innovation Alliance. Dr Chen has a double doctorate in economics and finance from the University of Chicago where he studied under the tutelage of 4 Economics Nobel laureates.
14:00 – 16:00
Private company showcase moderator
Alfred Li
Executive Director, UBS AG
Alfred is an Executive Director in the Asia Healthcare Group. Before joining the UBS Global Healthcare team in Jan 2016, he served as senior corporate finance associate in Jefferies and J.P. Morgan Securities. Alfred has extensive experience in the China healthcare industry and Hong Kong IPO execution process.
